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were used. Of these, 27 studies used telephone and text reminders. Four used 
educational materials and books while another four used blister packing. Three 
studies used interactive voice response system, two studies used letters and 
faxes, and another two studies used pill boxes. Improvement in medication 
adherence was found in all studies. The largest change in medication adherence 
was observed through the use of telephone and text reminders. CONCLUSIONS: 
Medication adherence is a problem that pharmacists are addressing through 
health care reform legislation. It’s important for pharmacists/researchers to 
educate about effective adherence tools in order to improve quality of care to 
patients and society.  
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OBJECTIVES: To explore evidence of the degree of correlation between patient 
reported outcomes (PROs) and clinician reported outcomes (ClinROs), and how 
this varies by therapeutic area, measure and language. METHODS: A review of 
the literature and analysis of existing patient registry data was conducted to 
qualitatively assess degree of correlation between PROs and ClinROs – at points 
in time, change over time, and how the relationship between these assessments 
varies by disease area and measure. A review of translation and linguistic 
validation projects involving PRO and ClinROs was also conducted to examine 
language-related differences and correlations between the scales. Specific 
examples of PRO-ClinRO pairs are given for multiple sclerosis, rheumatoid 
arthritis, and atopic eczema, among others. RESULTS: For multiple sclerosis and 
rheumatoid arthritis, moderate correlation (0.5-0.7) was found between patient 
assessments of disease severity and physician assessment, with patient 
assessments influenced by concomitant feelings (e.g., depression, anxiety). The 
correlation between patient and clinician assessment of change/responsiveness 
depends on whether an improvement or deterioration is experienced, where 
deterioration has a perceived stronger impact, patient-wise, than an 
improvement. Differences in language complexity and terminology between 
PROs and ClinROs were essential for the appropriate comprehension by the 
target population. Clinically appropriate and current terminology used for 
ClinROs was key to clinicians accepting the scale as relevant. Simple, clear 
phrasing and wording with language with lower education level was important 
for PROs. CONCLUSIONS: For reviewing PROs and ClinROs, specific differences in 
language and terminology must be taken into account, both in the development 
of instruments and linguistic validation into various target languages. In some 
disease areas, a significant and strong correlation of patient’s assessment with 
objective clinical measures may support its use as a valid proxy measure of 
clinical status, thus opening up multiple research design opportunities where 
the perspective of the patient is paramount.  
 
PRM165  
EXPLORING THE HUMANISTIC AND ECONOMIC BURDEN OF CROHN'S DISEASE: 
CONSIDERATIONS FOR NOVEL COMPOUNDS  
Hansen BB1, Kitchen H2, Heron L2, Gater A2, Walmsley S2, Pollard C2, Højbjerre L1, 
Strandberg-Larsen M1 
1Novo Nordisk A/S, Søborg, Denmark, 2Adelphi Values, Bollington, UK  
OBJECTIVES: Crohn’s disease (CD) is an inflammatory bowel disease affecting 
approximately 1.4 million people in the United States. The aims of this study 
were to document current unmet needs in CD in terms of patient-reported and 
economic burden; and how such concepts may be assessed to capture the overall 
benefit of new CD therapies for patients, health care systems and society. 
METHODS: Articles were identified in MEDLINE, EMBASE, EconLit, HEED, CRD 
databases and PSYCINFO using pre-defined search terms/limits. 561 abstracts 
were identified; and 31 full articles were reviewed. Direct and indirect costs of 
CD were extracted as were patient-relevant concepts (symptoms and impacts) to 
form a patient-relevant conceptual model. Patient-reported measures were 
identified in PROQOLID and were assessed in context of FDA guidance. RESULTS: 
CD symptoms manifest primarily as gastrointestinal disturbances including 
abdominal pain/cramping and diarrhoea. Fever, fatigue and weight loss are also 
prominent symptoms. These symptoms impact patients’ physical functioning, 
daily activities, emotional well-being, and ability to work. Seven patient-reported 
measures were reviewed in-depth; measures of HRQoL (IBDQ, SF-36, IBDQOL), 
occupational functioning (CPWDQ, WPAI:CD) and disease activity/symptoms 
(CDAI, CDAI-short, GSRS). Instruments to assess HRQoL and occupational 
functioning used concurrently with the CDAI may demonstrate the wider 
influence of treatment on other symptoms and patients’ lives. CD is associated 
with substantial direct costs, estimated at $18-$19,000 per-patient per-year in the 
US, and indirect costs, estimated at $7,260 per-patient per-year. Costs are 
especially high in sub-groups (e.g. presence of fistulas). CONCLUSIONS: The 
disease course of CD is characterised by remissions and relapses, thus lifetime 
humanistic and economic burden is substantial. This review highlights the need 
for disease-specific patient-reported measures that provide comprehensive 
assessment of relevant domains of disease activity/symptoms, HRQoL and 
occupational functioning. Further research into drivers of direct and indirect 
costs of CD is necessary to meet cost-effectiveness requirements.  
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OBJECTIVES: The FDA approved 39 new molecular entities (NMEs) in 2012, and 
many efficacy claims were supported by patient-reported measures or 
statements. In addition, many previously-approved products were approved for 
a new indication supported by PRO endpoints in recent years. The purpose of our 
research was to conduct an in-depth analysis of recently approved claims 
supported by PROs in order to identify notable trends, and to describe best 
methods for assessing the success rate of PRO inclusion. METHODS: Published 
FDA product labels, literature and Internet searches were utilized. All labels of 
NMEs and new indications approved by the FDA from 2010 to 2012 were 
reviewed. A measure or statement of efficacy was considered to be a PRO if it 
assessed symptoms, reduced side effects, or impacts on functioning from the 
patient’s perspective. RESULTS: There were 21, 30, and 39 NMEs approved in 
2010, 2011, and 2012. In these years, 12, 19, and 13 NME labels contained PRO-
related claims or statements (67%, 63%, 33%), and pain-related PROs were the 
most common (n’s=4, 11, 8). Cumulative distribution function (CDF) graphs were 
present in 13 NME labels during these years. Importantly, from 2010 to 2012 
many products added indications with efficacy claims supported by a PRO, but 
such a submission was not considered an NME (e.g., pregabalin). From 2006 to 
2009, PRO-related claims were included in 66% of approved NMEs. This rate 
decreased to 49% during 2010 – 2012; however, more PRO claims (44 versus 50; 
2010-2012) are revealed when reviewing more than NMEs. CONCLUSIONS: 
Development, testing, and validation of PRO measures as clinical trial endpoints 
remain important for facilitating the approval of drugs and communicating value 
to the consumer. Reviewing NDA and BLA labels is a more accurate assessment 
of the success of PRO inclusions in FDA-approved labels than reviewing NMEs 
alone.  
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OBJECTIVES: Apply data mining techniques to pharmacy data to identify 
patients likely to be non-adherent to their medication in the next six months. 
METHODS: Catalina Health™ receives a nationally representative sample of 
pharmacy data containing 40% of all U.S. retail prescription volume and 130 
million unique patient ID’s. The data is HIPAA compliant, longitudinal, and not 
projected. Select 7 prescription medications representing multiple therapeutic 
classes. For each medication, randomly select a 100K patient cohort filling a 
prescription between June and August 2010. In order to eliminate patients who 
switch pharmacies or migrate to mail order, exclude patients who have no 
history of filling any drug during the prior 18 months, or who have no fill history 
for any drug during the six month analysis period. Fit logistic regression models 
to predict which patients will be non-adherent to their medication in the next 
six months. Consider patients non-adherent when Proportion of Days Covered 
(PDC)<80%. Model covariates include prior adherence to the medication (if 
applicable), adherence for co-morbid conditions, days supply of the medication, 
ethnicity and income variables, patient age and gender, paid with cash, number 
of refills remaining, medication dose, and number of co-morbidities. Model 
accuracy is assessed using a 20% hold-out of the data. RESULTS: The models 
identified 40.3% of the patients as likely to be non-adherent to their medication 
in the next six months. This varied by medication (23.2% - 64.6%) and patient 
type (28.8% Experienced, 38.9% Moderate Experienced, and 77.5% New). The 
overall model accuracy rate is 70.4%. 72.3% of the patients predicted to be non-
adherent were actually non-adherent (precision), while 69.1% of the patients 
predicted to be adherent were actually adherent. CONCLUSIONS: Data mining 
techniques applied to pharmacy data can predict patients who are likely to be 
non-adherent to their medication in the next six months with 72.3% precision.  
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OBJECTIVES: Guidelines had present many management recommendations to 
physicians on angina prevention and treatment. However patients still knew less 
about angina management in China. They need Heart education. Thus, we want 
to develop an angina patient self-management questionnaire (ASMQ). 
METHODS: We hypothesized the questionnaire should carry messages of risk 
factors, prevention and treatment of angina. Items were determined from 
guidelines, and interview of patients and cardiovascular doctors. A five point 
Likert scale was chosed as the response format. Higher score means better 
management. The questionnaire was tested along with a cross-sectional angina 
study. Reliability was evaluated via internal consistency, and test-retest 
reliability. Construct validity was tested through Exploratory Factor Analysis 
(EFA), and discriminant validity was assessed by detecting differences between 
in-patients and out-patients. We assumed in-patients learn more about angina 
than out-patients. RESULTS: The ASMQ contained 12 items organized in two 
domains: risk-factor and self-management. The ASMQ was tested on 430 
patients (age 63±12 year; 171 male, 40%); Of those, 150 (35%) were outpatients, 
and 86 (20%) retested 24 hours later. Test-rest correlation coefficient of the ASMQ 
was 0.740, and 0.719, 0.780 for risk-factor and self-management domains 
respectively. Cronbach’s alpha coefficient was 0.616 of the overall questionnaire, 
and 0.692 of the self-management domain. But the risk-factor domain was 0.432, 
showed an unsatisfied internal consistency. Three factors were extracted 
through EFA, and were stratified into 2 domains as expected. The score of in-
patients (43±7) was higher than out-patients (41±6), which showed a better 
management among in-patients (p=0.017). CONCLUSIONS: The ASMQ showed an 
